Mitral Insufficiency (MI) – A Complete Patient Guide

Overview

Mitral insufficiency, also called mitral regurgitation (MR), is a condition in which the mitral valve – the door between the left atrium and left ventricle of the heart – does not close tightly. This allows blood to leak backward into the left atrium each time the ventricle contracts. Over time, the extra volume can stretch the heart muscle and lead to heart failure if left untreated.

• Who it affects: Adults of any age, but the most common groups are:
  • Older adults ≥ 65 years (degenerative valve disease)
  • People with a history of rheumatic fever (more common in developing countries)
  • Patients with connective‑tissue disorders (e.g., Marfan syndrome)
• Prevalence: In the United States, moderate‑to‑severe MR is present in roughly 2 % of adults aged ≥ 75 years (≈ 2.5 million people) and around 0.2 % of the general adult population (Mayo Clinic, 2023). Worldwide, rheumatic heart disease accounts for up to 15 % of MR cases in low‑income regions (WHO, 2022).

Symptoms

Many people with mild mitral insufficiency have no symptoms and are diagnosed incidentally on an echo. When symptoms appear, they tend to worsen gradually as the regurgitant volume increases.

Common symptoms

• Dyspnea on exertion – Shortness of breath during activities such as climbing stairs or walking a block.
• Fatigue / decreased exercise tolerance – The heart works harder, leading to early tiredness.
• Palpitations – Irregular or rapid heartbeats, often due to atrial fibrillation.
• Orthopnea – Difficulty breathing when lying flat; may need a pillow or elevated head.
• Paroxysmal nocturnal dyspnea (PND) – Sudden nighttime shortness of breath that awakens the patient.
• Chest discomfort – A vague pressure or tightness, not typical of ischemic pain.
• Swelling (edema) – Usually in the ankles or feet, indicating fluid buildup.

Red‑flag symptoms that suggest worsening disease

• Rapid weight gain (> 2 kg in a week) due to fluid retention.
• Sudden onset of severe shortness of breath at rest.
• Fainting (syncope) or near‑syncope during activity.
• Persistent cough with frothy or pink‑tinged sputum.

Causes and Risk Factors

Mitral insufficiency can be divided into two broad categories: primary (or organic) and secondary (functional).

Primary (organic) mitral regurgitation

• Degenerative (myxomatous) disease – The valve leaflets become thickened and redundant (e.g., prolapse). This is the most common cause in developed countries.
• Rheumatic heart disease – Inflammation and scarring after rheumatic fever can fuse leaflets.
• Infective endocarditis – Bacterial infection destroys valve tissue.
• Congenital abnormalities – Bicuspid mitral valve or cleft leaflets present from birth.
• Trauma or iatrogenic injury – Chest injury or complications from cardiac surgery.

Secondary (functional) mitral regurgitation

• Left‑ventricular dilation – Due to ischemic heart disease, cardiomyopathy, or chronic hypertension, the papillary muscles are displaced, preventing proper leaflet coaptation.
• Heart failure with reduced ejection fraction – The ventricle stretches, pulling the valve apart.

Risk factors

• Age > 60 years
• Male sex (slightly higher incidence of degenerative MR)
• History of rheumatic fever or untreated streptococcal infections
• Hypertension, coronary artery disease, or prior myocardial infarction
• Connective‑tissue disorders (e.g., Marfan, Ehlers‑Danlos)
• Family history of valvular disease
• Excessive alcohol use (can cause dilated cardiomyopathy)

Diagnosis

Diagnosis relies on a combination of clinical evaluation and imaging.

Physical exam

• Holosystolic (pansystolic) murmur best heard at the apex, radiating to the axilla.
• Presence of an S3 gallop (sign of volume overload).
• Elevated jugular venous pressure if severe.

Imaging & tests

• Transthoracic echocardiography (TTE) – First‑line; assesses severity, left‑atrial size, ventricular function, and pulmonary pressures. Quantifies regurgitant volume and effective regurgitant orifice area (EROA).
• Transesophageal echocardiography (TEE) – Provides detailed valve anatomy, especially before surgical or percutaneous repair.
• Cardiac MRI – Offers precise measurements of ventricular volumes and function; useful when echo windows are poor.
• Electrocardiogram (ECG) – Detects atrial fibrillation, left‑bundle branch block, or evidence of prior myocardial infarction.
• Chest X‑ray – May show enlarged left atrium, pulmonary congestion, or pleural effusion.
• Stress testing – Determines exercise tolerance and triggers for symptom onset in borderline cases.
• Cardiac catheterization – Reserved for patients being evaluated for coronary artery disease before valve surgery.

Treatment Options

Management is individualized based on symptom severity, degree of regurgitation, ventricular function, and comorbidities.

Medication

• Afterload‑reducing agents – ACE inhibitors, ARBs, or hydralazine lower systemic resistance, decreasing the back‑flow volume.
• Beta‑blockers – Reduce heart rate and improve ventricular filling; helpful if atrial fibrillation co‑exists.
• Diuretics – Relieve pulmonary congestion and peripheral edema.
• Anticoagulation – Indicated for patients with atrial fibrillation or a history of thromboembolism (warfarin or DOACs).
• Mineralocorticoid receptor antagonists – May be added in chronic heart‑failure settings.

Interventional & Surgical Options

1. Percutaneous Mitral Valve Repair (MitraClip®) – A catheter‑based edge‑to‑edge repair that clips leaflets together. Ideal for high‑risk surgical patients with symptomatic severe MR (ACC/AHA class IIa recommendation).
2. Surgical Mitral Valve Repair – Preferred when the valve anatomy is amenable; preserves native valve and offers superior long‑term durability.
3. Surgical Mitral Valve Replacement – Considered when repair is not feasible. Choice between mechanical (lifelong anticoagulation) or bioprosthetic (limited durability) prostheses depends on age and comorbidities.
4. Left‑ventricular assist devices (LVAD) or heart transplantation – Reserved for end‑stage heart failure when valve correction alone cannot restore function.

Lifestyle & Self‑care

• Limit sodium intake to < 2 g per day and avoid excess fluid if instructed by a physician.
• Engage in moderate aerobic activity (e.g., brisk walking) 150 min/week as tolerated; avoid high‑intensity bursts that provoke breathlessness.
• Maintain a healthy weight (BMI 18.5–24.9 kg/m²) to reduce cardiac workload.
• Quit smoking and limit alcohol (< 1 drink/day for women, < 2 for men).
• Monitor blood pressure regularly; keep it < 130/80 mmHg.
• Adhere to prescribed medication schedule and attend all follow‑up appointments.

Living with MI (Mitral Insufficiency)

Long‑term management focuses on symptom control, preserving heart function, and preventing complications.

Daily Management Tips

• Weight‑tracking: Weigh yourself daily; a gain of > 2 kg in 3 days warrants contacting your clinician.
• Activity pacing: Use the “talk test” – you should be able to speak a full sentence without gasping.
• Medication diary: Record dose times and any side effects; bring the list to every visit.
• Vaccinations: Stay up‑to‑date on influenza, COVID‑19, and pneumococcal vaccines to avoid respiratory infections that stress the heart.
• Dental hygiene: Good oral care reduces risk of infective endocarditis; discuss prophylaxis with your cardiologist before invasive dental work.
• Support network: Join a heart‑failure or valve‑disease support group—sharing experiences improves coping.

Follow‑up Schedule

• Echo every 1–2 years for mild/moderate MR with normal ventricular function.
• Every 6‑12 months if symptoms develop or if left‑ventricular ejection fraction (LVEF) falls < 60 %.
• Immediate review if new palpitations, worsening dyspnea, or edema occur.

Prevention

While you cannot change genetic predisposition, many modifiable factors lower the risk of developing or worsening mitral insufficiency.

• Prompt treatment of streptococcal throat infections – Reduces the chance of rheumatic fever.
• Control hypertension and coronary artery disease – Target BP < 130/80 mmHg and LDL < 70 mg/dL in high‑risk patients (ACC/AHA 2024 guidelines).
• Healthy lifestyle – Regular exercise, balanced diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids.
• Avoid illicit drug use – Cocaine and amphetamines can precipitate cardiomyopathy.
• Regular medical check‑ups – Early detection of mild regurgitation before it progresses.

Complications

If left untreated, severe mitral insufficiency can lead to several serious complications.

• Left‑atrial enlargement – Predisposes to atrial fibrillation and thrombus formation.
• Pulmonary hypertension – Backward pressure transmission to the lungs causing right‑heart strain.
• Heart failure (HFpEF or HFrEF) – Reduced exercise capacity, edema, and mortality risk increase.
• Endocarditis – Turbulent flow creates a nidus for bacterial colonization.
• Stroke – Atrial fibrillation or atrial thrombus can embolize.
• Sudden cardiac death – Rare, but possible in the setting of severe ventricular dysfunction.

When to Seek Emergency Care

---

References:

• Mayo Clinic. “Mitral valve regurgitation.” Updated 2023. https://www.mayoclinic.org
• American College of Cardiology/American Heart Association. 2024 Guideline for the Management of Valvular Heart Disease.
• World Health Organization. “Rheumatic heart disease.” 2022. https://www.who.int
• Cleveland Clinic. “Mitral Regurgitation.” 2024. https://my.clevelandclinic.org
• National Institutes of Health. “Heart valve disease.” 2023. https://www.nhlbi.nih.gov